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Abstract
Inhibition of the sodium–hydrogen exchanger (NHE) is a powerful experimental tool to inhibit
sodium and calcium accumulation within the ischemic myocyte and halt progression of cell
ischemia to cell necrosis. This paper describes the protocol and rationale of a first large-
scale clinical trial designed to evaluate the safety and efficacy of cariporide, a novel specific
and potent inhibitor of the exchanger.
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CABG = coronary artery bypass grafting; CK = creatine kinase; DSMB = Data and Safety Monitoring Board; ECL = Electrocardiography Core Lab-
oratory; EVC = End-point Validation Committee; IC50 = 50% inhibitory concentration; MI = myocardial infarction; NHE = sodium–hydrogen
exchanger; PCI = percutaneous coronary intervention; UA/NSTEMI = unstable angina and non-ST-segment elevation myocardial infarction.
Background: Direct myocardial cell protection in patients with
unstable angina or evolving myocardial infarction (MI) could
prevent cell necrosis or reduce its extent, and minimize the risk
of MI and death associated with percutaneous coronary
interventions (PCIs) and coronary artery bypass surgery. The
myocardial NHE plays a critical role in mediating the
progression of ischemia to necrosis by promoting intracellular
accumulation of sodium and calcium in exchange for hydrogen.
Blockage of the system in various experimental models of
ischemia and reperfusion had a strong antinecrotic effect. The
present paper describes a trial that was intended to investigate
the potential clinical benefit of cariporide, a potent and
selective inhibitor of the NHE, in a large spectrum of at-risk
patients.
Trial design: The GUARDIAN trial was a multicenter, double-
blind, randomized, four-arm trial that compared three
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Introduction
The acute coronary syndromes involve a cascade of
events that can culminate in MI and death [1]. Current
therapy targets control of thrombus formation on an
active culprit coronary plaque. Antithrombotic therapy
with or without a reperfusion procedure significantly
reduces the ischemic event rate. Treatment, however,
often fails to prevent irreversible cell damage, and proce-
dures can lead to cell necrosis. The left ventricular
damage results in a variable amount of left ventricular
dysfunction, which is the major determinant of subse-
quent prognosis and cardiac disability.
Although direct cell protection has been a long-term
concern and the focus of numerous investigations, no
intervention has so far gained widespread clinical applica-
tion [2]. Meanwhile, the cellular mechanisms involved in
cell ischemia and cell necrosis have become acknowl-
edged, leading to the development of new protective
agents and opening new therapeutic perspectives.
In this line, the role of the NHE in ischemia and reperfu-
sion injury has recently been characterized [3]. The NHE
exchangers comprise a family of membrane proteins that
are involved in the transport of hydrogen in exchange for
sodium, utilizing the transmembrane sodium gradient as
the driving force [4]. They are regulated by the intracellu-
lar pH through interaction of hydrogen with a sensor site
of the exchanger protein and by many other driving forces
that are generally receptor mediated.
Six NHE isoforms have been recognized [5]. NHE-1 is ubiq-
uitously distributed in tissue, and is the predominant NHE
isoform in the myocardial cell. It is rapidly activated during
ischemia by intracellular hydrogen accumulation that is
exchanged for sodium. The intracellular accumulation of
sodium in turn leads to an increase in intracellular calcium
concentrations via sodium–calcium exchange as the ATP-
dependent sodium–potassium exchanger becomes inoper-
ative (Fig. 1) [6]. Elevated intracellular calcium
concentration directly mediates cell death by activation of
various proteases and by causing cell contracture and
membrane rupture. The activity of the NHE system is self-
limited during prolonged ischemia once an ionic equilibrium
is reached between the extracellular and intracellular
spaces, but is intensified upon reperfusion by washout of
the acidic extracellular fluid [7]. The massive entry of
calcium into the cell during reperfusion precipitates cell con-
tracture and contraction band necrosis [3].
Cariporide (HOE642A) was developed recently as a
selective inhibitor of the NHE exchanger [8]. The drug is a
benzoylguanidine with a molecular weight of 379.46Da.
Inhibition of the activity of the system has been docu-
mented experimentally in endothelial cells, myocytes, ery-
throcytes and platelets [8]. Internal data has shown a
dose-dependent inhibition of the NHE system in platelets,
with 100% inhibition reached within 15 min after the injec-
tion of a bolus dose of 60mg, declining to approximately
50% after 4h. The elimination half-life is about 3.5h.
Cardioprotective effects of cariporide have consistently
been documented in various experimental models of
ischemia/reperfusion, with marked reduction in infarct size
when NHE inhibitors were administered before or early
during ischemia [9]. Higher doses of the inhibitors admin-
istered before reperfusion are still effective [10,11]. Cari-
poride was administered safely in 20 patients undergoing
aortic valve surgery and bypass surgery. In another pilot
study [12], in patients with an evolving anterior MI under-
going direct revascularization, administration of this drug
has shown promising results.
Full article
cariporide dosages with placebo in patients with unstable
angina and non-ST-segment elevation myocardial infarction
(UA/NSTEMI) and in patients undergoing a high-risk PCI or
coronary artery bypass surgery. A total of 11590 patients with
one of the three possible entry diagnoses were enroled in 23
countries. The trial was designed as a combined phase
2/phase 3 study. The primary objective was to evaluate the
efficacy of cariporide in reducing all-cause mortality and/or MI
across the various entry populations 36 days after
randomization. Three different doses of cariporide were
compared with placebo. Secondary end-points were death or
non-fatal MI at 10 days and 6 months, and cardiac events
related to left ventricular dysfunction. The extent of MI was
also assessed by peak elevation in creatinine kinase (CK)-MB
and a ratio of peak elevation to normal values. The sample size
was driven by a total event rate of 1200 patients experiencing
a primary end-point, powered to detect a 25% risk reduction
in any of the three treatment groups compared with placebo at
a significance level of 0.02, accounting for the three pairwise
comparisons.c
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The GUARDIAN trial was the first large-scale trial
designed to assess the potential protective effect of NHE
inhibition in humans. The four-arm trial was double-blind,
randomized, and placebo-controlled. It was designed as a
combined phase 2/phase 3 study to evaluate the potential
of cariporide to prevent necrosis across various situations
that involve myocardial ischemia, such as UA/NSTEMI,
PCI, and coronary artery bypass grafting (CABG).
Trial organization
The study was sponsored by Aventis Incorporated (New
Jersey, USA). The Steering Committee supervised the
organization and scientific conduct of the GUARDIAN
study. An independent Data and Safety Monitoring Board
(DSMB), composed of four physicians and one statisti-
cian, was responsible for safety, side effects, critical
event monitoring and ethical aspects. The Chairman of
the DSMB received and reviewed online individual
reports of all unexpected associated serious adverse
events. Quarterly overall safety reports were generated by
the DSMB and submitted to the Steering Committee and
the sponsor. An End-point Validation Committee (EVC)
and an Electrocardiography Core Laboratory (ECL)
located at St Louis University, St Louis, Missouri, USA,
shared the responsibility of adjudicating all end-points of
the trial, including secondary end-points. A total of 382
clinical centers from 23 countries actively participated in
the study. Worldwide data collection, study monitoring,
and data management were performed by Quintiles Incor-
porated (Research Triangle Park, NC, USA).
Study design
A general overview of the trial design is provided in Fig. 2.
Patient selection
Patients of either sex and of any race, aged 18 years or
more, presenting with UA/NSTEMI or undergoing a PCI or
CABG could be enroled, as long as some high-risk fea-
tures were present (as described in detail under Inclusion
criteria, below). Approval by regulatory agencies of the
various countries, as well as from all Institutional Review
Boards and Ethical Committees concerned, was sought
before the start of the study, and signed informed consent
was obtained from all patients before enrolment. It was
expected that patients with UA/NSTEMI would represent
40–50% of the trial population, patients undergoing a
high-risk PCI 30–40%, and patients undergoing high-risk
CABG 10–20%.
Inclusion criteria
The inclusion criteria for the UA/NSTEMI entry category
were repetitive (³ two episodes of ³5 min duration) or pro-
longed (³ one episode of ³20 min duration) angina chest
pain at rest or on minimal exercise within 12h before ran-
domization, with one of the following electrocardiographic
or laboratory findings: ST-segment depression >1mm in
at least two contiguous leads; T-wave inversion >1.5mm
in at least three contiguous leads; transient ST-segment
elevation >1mm with duration of <30 min in at least two
contiguous leads; total CK and/or CK-MB >1.5 times
upper limit of the normal range; and troponin I >2.0mg/l or
troponin T >0.15mg/l. Patients presenting with angina at
rest or on minimal exercise 12h to 4 weeks after an acute
MI could also be included in the study, regardless of
whether they had received immediate PCI or thrombolysis
or met any of the above criteria for acute ischemia.
Figure 1
Ions exchange during ischemia and reperfusion and consequence of
inhibition of the NHE. Ischemia results in rapid intracellular acidosis as
the metabolism becomes anaerobic, activating the pH-regulating ion
transporters and the NHE. This results in a large influx of sodium (Na+)
into the cell. As the ATP supply for the Na+/potassium (K+) pump falls,
Na+ accumulates within the cell, reducing calcium (Ca2+) efflux and/or
promoting reverse mode Ca2+ entry (3Na+/Ca2+). The exchange is self-
limited as extracellular protons accumulate, but is reactivated upon
reperfusion by the washout of the acidotic extracellular fluid, reactivating
the NHE system for an accumulation of ions within the cell. NHE
inhibition markedly reduces this Na+ and Ca2+ overload. H+, hydrogen.
Figure 2
Study protocol. E, enrolment; FE, follow-up evaluation; PE, primary
evaluation; R, randomization.The criteria for inclusion in the PCI entry category were
history of angina at rest or on minimal exercise within the
past 4 weeks, with any approved PCIs planned in the fol-
lowing hours for a lesion with at least two type B or one
type C characteristic [13].
For CABG, the criteria were an urgently required interven-
tion (eg following failed PCI), repeat CABG, and candi-
dates with a history of angina at rest or minimal exercise
within the past 4 weeks and with the presence of two or
more of the following features: age >65 years; female sex;
diabetes mellitus; left ventricular ejection fraction <35%;
and left main or three-vessel disease.
Exclusion criteria
The protocol criteria for exclusion were persistent
(³30 min) ST-segment elevation (>1mm), or new
ST-segment elevation MI, a secondary cause of unstable
angina (eg anemia, hyperthyroidism, arrhythmias), and
cardiogenic shock or pulmonary edema refractory to
medical treatment. Other exclusion criteria were as
follows: previous exposure to the drug; history of hyper-
sensitivity to amiloride (a structurally related compound);
noncardiac progressive fatal disease; known ALAT and
ASAT levels exceeding three times the upper limit of
normal or known bilirubin >1.75mg/dl (>30mmol/l);
known serum creatinine levels >2.0mg/dl (>177mmol/]);
or clinical evidence of severe hepatic or renal impairment.
Pregnancy or potential for pregnancy in the absence of
reliable contraception, breast-feeding, alcohol abuse,
potential for noncompliance, and mental inaptitude were
also exclusion criteria.
Randomization and study drug administration
The study ran four parallel groups: one placebo group and
three treatment arms with doses of cariporide of 20, 80, or
120mg, respectively, administered in a volume of 50ml in
a 60 min infusion three times daily at intervals of 8h. The
randomization schedule linked sequential numbers to
treatment codes allocated at random on a 1:1:1:1 basis.
The subjects were numbered at each center, in the order
in which they were enroled. The study drug was initiated
as soon as possible after hospital admission in patients
randomized for an UA/NSTEMI, and between 15 min and
2h before the intervention in patients randomized for
planned PCI or CABG.
The treatment duration could vary from 2 days (six doses)
to 7 days (21 doses) to cover the period of risk of MI, as
evaluated by the treating physician and the local investiga-
tors. The recommendation was made to discontinue the
drug when the patient was clinically stable with a
symptom-free period of 12–24h, with no further interven-
tion planned. The drug could also be discontinued before
2 days in patients discharged earlier after an uneventful
percutaneous procedure.
In patients with impaired renal function, the dosage of the
drug was to be adjusted downward. Patients with serum
creatinine level between 1.5 and 2.0mg/dl
(133–177mmol/l) before randomization received a full
dose at the first injection and half the doses subsequently.
The dose of the drug was halved in patients who devel-
oped this increase in creatinine during the course of the
study. Patients with a baseline creatinine level >2.0mg/dl
(>177mmol/l) were excluded, whereas the study drug was
discontinued during the study when the creatinine levels
increased to >3.0mg/dl (>265mmol/l).
Study end-points
The primary end-point of the trial was the combined inci-
dence of all-cause mortality or MI measured 36 days after
randomization. The secondary end-points were as follows:
the rate of the primary composite end-point at 10 days;
events related to left ventricular dysfunction (defined as
cardiac-related mortality, cardiogenic shock, overt conges-
tive heart failure, and life-threatening arrhythmia) evaluated
36 days and 6 months after randomization; the extent of
infarction as assessed by peak CK-MB elevation and a
ratio of elevation; and occurrence of refractory ischemia
within 36 days. End-points were both analyzed for the
overall population and for the three entry categories
(UA/NSTEMI, PCI and CABG).
Serial electrocardiographs and CK-MB determinations
were obtained as part of the protocol. A 12-lead electro-
cardiograph was obtained before randomization and
after 24h, 10 days (or at discharge if earlier), and 36
days. All centers had to determine the CK-MB values, at
least when the total CK values were elevated. Routine
determinations were performed before randomization
and at 4, 8, 12, and 24h after randomization in patients
with UA/NSTEMI and in those undergoing PCI, and at 8,
12, 16, and 24h after surgery in patients undergoing
CABG. The sequence of blood sampling was repeated
whenever the patient experienced chest pain with dura-
tion of 20 min or longer during the hospital stay. The 12-
lead electrocardiograph was also repeated during chest
pain and 24h later. When patients had suspect MI
events after hospital discharge, the investigator was
requested to supply the more diagnostic electrocardio-
graph(s) and results of serum markers associated with
the event.
Cardiac-related mortality was defined as sudden cardiac
death, death due to circulatory failure, or death due to
another cardiovascular disease, such as perioperative
death, or aortic, cerebral, mesenteric or peripheral vascu-
lar disease. Noncardiac mortality included all other causes
of death that were not directly the consequence of the
underlying cardiac disease or of an intervention proce-
dure, such as infection, respiratory failure, trauma, and
suicide.
Current Controlled Trials in Cardiovascular Medicine    Vol 1 No 1 Theroux et alThe diagnosis of MI was based on electrocardiograph or
CK-MB criteria, with or without chest pain. Infarcts were
classified as Q-wave or non-Q-wave MI. Q-wave MI was
defined by appearance of new Q-waves that occurred
after randomization (between 24h and 36 days). Non-
Q-wave MI was defined as the appearance of abnormal
CK/CK-MB in the absence of Q-wave criteria. Criteria for
abnormal CK/CK-MB elevation were more than two times
the upper limit of normal in patients with UA/NSTEMI, and,
if within 24h of a revascularization procedure, more than
three times the upper limit of normal after PCI and more
than 100 units/l within 24h after CABG. For enzyme ele-
vation that occurred more than 24h after a PCI or CABG,
the criteria for UA/NSTEMI were used.
All electrocardiograph tracings were analyzed at the ECL
using the Minnesota code [14]. Serial comparisons of
consecutive electrocardiographs were performed using an
adaptation of the Novacode for Q-wave items [15,16]. The
St. Louis University ECL uses supplemental Q-wave
codes to detect the lesser degrees of Q-wave abnormal-
ity, as well as criteria for true posterior infarction (new
appearance of a 40-ms R wave and R/S >1 in lead V2).
Grade 1 or grade 2 ST- or T-wave worsening were classi-
fied according to the Minnesota code and assigned to the
anterior (leads V1–V5), inferior (leads 2, 3, aVF), lateral
(leads 1, aVL, V6), and posterior (leads V1, V2).
In order to differentiate an entry from outcome MI in
patients with UA/NSTEMI, patients with normal CK/
CK-MB measurements before randomization and 8h after
randomization were specifically examined. When the mea-
surements were normal before randomization and up to
8h after randomization, an outcome MI was diagnosed if
CK/CK-MB values exceeded two times the upper limit of
normal after 8h or more in the UA/NSTEMI group, or if
they exceeded two times the upper limit of normal in the
24h after a PCI. When CK-MB values were abnormal at
baseline or up to 8h, the patient was diagnosed as having
an entry MI. Special criteria were used to define a reinfarc-
tion in this setting. For those with elevated CK-MB, more
than two times the upper limit of normal within 8h after
randomization, and with a decrease in CK-MB of more
than 50% from the previous peak value, reinfarction was
defined as an elevation of the value of CK-MB at or after
8h to more than two times the upper limit of normal (three
times in the case of PTCA) and 75% more than the pre-
ceding trough CK-MB values. When baseline CK-MB was
more than two times the upper limit of normal, a new
episode of chest pain and new ST-segment shifts were
required in addition to the 50% elevation over the preced-
ing trough and an increase to more than two times the
upper limit of normal (three times after PCI). In subjects in
whom CK-MB was elevated at baseline or during the first
8h after randomization, and the CK-MB value decreased
by more than 50% from the peak value, chest pain and
new ST-segment changes were not required. The diag-
nostic criterion for MI related to CABG was an elevation of
the CK-MB values to more than 100 units/l within the 24h
that followed surgery. Other information, such as autopsy
reports, could also be used for the diagnosis of MI.
Estimates of infarct size were obtained by using the peak
CK-MB elevation values observed during the first 24h after
randomization and the distribution of a ratio formed by the
peak value to the baseline values. For the purpose of com-
paring infarct sizes between the various entry diagnoses, an
equivalence table was constructed using the twofold
increase criterion for the diagnosis of MI in patients with
UA/NSTEMI, and the threefold increase with PCI-related MI;
for a CABG-related MI, the peak values were used (Table 1).
To account for the wide variation observed in the upper limit
of normal between the different laboratories, further post hoc
analyses were defined also to compare peak CK-MB values
in CABG patients as ratios to the upper limit of normal.
End-point validation
All suspected end-point events occurring during the study
were documented on an end-point form and validated by
the EVC and/or by the ECL. In order to facilitate proce-
dures, the EVC was divided into American and European
subcommittees. The homogeneity of the validation
process by the two subcommittees was regularly checked
in open meetings between the two co-Chairmen and also
by blind cross-adjudication of randomly selected case
report forms. The ECL screened all case report forms of
randomized patients for presence of myocardial ischemia
and of MI at entry and during the 36-day follow up in order
to validate reported events and to detect the unreported
ones, helped by the source documents. Two members of
the EVC independently reviewed all other clinical events,
as well as unreported MIs identified by the ECL. Any dis-
crepancy in adjudication was referred to one of the two
Chairmen of the EVC for final adjudication. The Chairmen
also reviewed all investigator-reported MIs validated or not
by the ECL. The Chairmen of the ECL and of the EVC met
regularly to reconcile, by consensus decision, any remain-
ing queries in the adjudication process. The sponsors,
members of the Steering Committee, of the EVC and of
the ECL, were blinded to the treatment assignment until
the database was cleaned after completion of the study.
Study performance
After discharge from hospital, the subjects entered a 6-
month follow-up phase, during which they kept a diary doc-
umenting further clinical events. The patients were
requested to return to the hospital 36–46 days after ran-
domization for a follow-up visit and recording of a 12-lead
electrocardiograph. They were contacted 6 months after
randomization to establish their life status and whether they
had suffered a MI or been rehospitalized. The discharge
form and a summary of rehospitalization were obtained.
http://cvm.controlled-trials.com/content/1/1/059
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Sample size
The sample size of 2250 patients per group in the
GUARDIAN trial was calculated on the basis of an esti-
mated 15% primary end-point event rate for the placebo
group (10–15% in UA/NSTEMI and PCI, and 20–25% in
CABG patients), an expected 25% relative risk reduction
in the active treatment group, and a target significance
level of 0.017 (0.05/3, accounting for the three pairwise
comparisons) detected with 90% power. Assuming that
the higher two doses of cariporide would be effective and
that the lowest dose would be similar to placebo, approxi-
mately 1200 patients with primary end-point events were
to be expected with a total sample size of 9000 patients.
The total information on 1200 patients with a primary
outcome event was required to determine the actual
number of patients recruited. Upon a planned blinded
event rate re-estimate, the overall sample size was
adjusted to 11500 patients because of a lower than
expected event rate.
Statistical analyses
For the primary composite end-point of all-cause mortality
and MI at day 36 after randomization, a nonparametric
covariance adjustment analysis method [17] was used to
calculate the P value and the 98% confidence limits. This
analysis requires only the randomization assumption, main-
tains the same interpretation for the estimators of the
event rate differences across different specifications of
covariates, and reduces variance of these estimators com-
pared with an unadjusted analysis. The variables prede-
fined before unblinding as covariates for this analysis were
as follows: age, sex, MI at entry, ST-segment depression,
congestive heart failure, diabetes, previous MI, and cere-
brovascular or peripheral vascular disease. The entry diag-
nosis groups were treated in the analysis as strata. In
support of this primary efficacy analysis, the square root of
the unadjusted c2 statistic was calculated and the times to
the first primary end-point event data were displayed using
Kaplan–Meier survival curves.
The secondary incidence data were analyzed by the same
covariance adjustment method as for the primary end-
point, and the extent of infarction, as assessed using peak
CK-MB scores, was evaluated by the extended Mantel–
Haenszel statistic with standardization within strata ranks.
The test statistic applied the proportional odds model, with
diagnosis group and treatment as independent variables.
In addition to the predefined analyses on the primary and
secondary efficacy end-points, it was planned to perform a
number of exploratory analyses in accordance with the
phase 2 design of the trial, in order to understand better
the modalities for potential benefit of the drug and of the
new pharmacologic approach. Such analyses considered
were an efficacy analysis, including only treated patients, all
patients who underwent PCI or CABG while on treatment,
patients with an MI or not at the time of randomization, and
patients with some degree of renal failure.
Two interim analyses by the DSMB were planned after
400 and 800 subjects with primary end-point events had
been identified. If the DSMB contemplated giving a rec-
ommendation concerning the future conduct of the trial,
these results were also to be reviewed blindly by the
Chairman of the Steering Committee and representatives
of the sponsor. The statistical decision guidelines to be
used for early stopping of the trial were based on the pro-
posals of Hwang et al [18] and Chang et al [19]. Early
stopping for a specific dose group could occur due to
overwhelming efficacy or as a result of the lack of efficacy.
Adverse events
All adverse events were coded according to the Hoechst
Adverse Reactions Terminology System, and were classified
by the main body system involved. Fisher’s exact tests were
used for comparison of active treatment and placebo
groups. Predefined events of special interest were studied
separately. These were arrhythmia, congestive heart failure
and shock, myocardial ischemia, altered mental status, acute
renal failure, allergic reactions, liver toxicity, hypotension,
stroke, and transient ischemic attack. Because of a concern
raised in phase 1 studies of a possible effect of cariporide on
blood pressure, the first 400 patients underwent serial blood
pressure measurements during the treatment phase.
Discussion
Most agents that protect myocardial cells against ischemic
injury act indirectly by favorably influencing the balance
between oxygen demand and supply, the latter being par-
ticularly effective in modifying the  prognosis of the disease
[2]. Agents that could directly protect the ischemic cell
against necrosis would have an important role in treatment,
and could magnify the benefit of various other treatment
Current Controlled Trials in Cardiovascular Medicine    Vol 1 No 1 Theroux et al
Table 1
Scores used to compare the extent of infarction between the
various entry diagnoses
Score UA/NSTEMI High-risk PCI High-risk CABG*
0 £ULN £ULN £60 U/l
1 >ULN, £2×ULN >ULN, £3×ULN >60 U/l to £100 U/l
2 >2*ULN, £5×ULN >3×ULN, £5×ULN >100 U/l to £200 U/l
3 >5*ULN, £10×ULN >5×ULN, £10×ULN >200 U/l to £300 U/l
4 >10×ULN >10×ULN >300 U/l
Patients who died from an acute MI were given a score of 4. *For
CABG-related MIs, the peak value during the first 24h after surgery
was also used, as was the mean of a ratio between the peak values
during the first 24h to the laboratory upper limit of normal. ULN, upper
limit of normal of local laboratories for the CK-MB values.forms. A number of interventions that target different patho-
physiologic mechanisms involved in cell necrosis are cur-
rently under evaluation for this purpose. The GUARDIAN
trial was designed to investigate one of these promising
interventions, the inhibition of the NHE by cariporide.
The NHE is believed to play an important role in contribut-
ing to cell necrosis by promoting sodium and calcium
entry within the cell in exchange for the accumulating
protons [3–5,9]. Giving the novelty of the approach and of
the pharmacologic agent evaluated, the trial design
required many assumptions. This was primarily reflected in
its phase 2/phase 3 design.
Study design and end-points
A major challenge of the GUARDIAN trial was its phase 2/
phase 3 design. The phase 2 components included selec-
tion of various doses in an attempt to define a dose–
response relationship for safety and efficacy, and of
patients with heterogeneous entry diagnoses, assuming
an important role of the NHE across various clinical situa-
tions involving ischemic tissue that is at risk of necrosis.
Overall, the study had four treatment arms and three differ-
ent entry diagnoses for a total of 12 groups.
The phase 3 component included the clinical end-points of
death or MI in order to document drug efficacy. Selection
of these convincing end-points was motivated by the
absence of a direct marker of myocardial effects of the
drug and of surrogate markers of efficacy, such as hemody-
namic or antithrombotic parameters. Although the experi-
mental data have measured efficacy in terms of infarct size
reduction rather than infarct prevention, the latter was
selected as the primary end-point considering the wide
variability in infarct size in humans in the absence of reliable
markers of area at risk and area of necrosis. Other valuable
clinical markers of efficacy could be improved global and
regional left ventricular function in states of ischemia and
reperfusion and of reversible left ventricular dysfunction,
such as stunning and hibernation that can be favorably
influenced by treatment [9]. No effects on recurrent
ischemia were expected. The relatively infrequent occur-
rence of MI in unstable angina and the wide spectrum in
severity when it occurs mandates a large sample size to
detect drug effect. The trial was powered to detect a 25%
reduction in risk, and to permit a reliable evaluation of drug
safety and of the modalities for a potential benefit in a large
spectrum of patients with coronary disease and an immedi-
ate risk of MI and death. Infarct size, which was assessed
as a secondary end-point, was measured by the distribu-
tion of outcome MIs as non-Q-wave versus Q-wave MI and
by the peak elevation in CK-MB values.
Entry diagnoses
A strong incentive to the choice of the primary end-point
of prevention of death or MI was the experimental findings
that NHE inhibition yielded maximal benefit when applied
before coronary occlusion or early during ischemia rather
than before reperfusion [8,10,11]. Accordingly, target
populations of patients who were at risk for myocardial cell
necrosis either as a result of the disease process or of an
intervention procedure were selected. Unstable angina
and non-ST-segment MI are situations of repeated periods
of ischemia. These alternate with periods of reperfusion
related to distal microembolization and progression of the
occlusion at the plaque level, yielding microinfarcts and
larger infarcts respectively, and infarct extension. In PCI
and CABG, the drug was administered immediately before
the period of risk. An algorithm was developed to differen-
tiate an outcome MI occurring after randomization from
evolving MIs at the time of randomization. Although the
various categories of patients had a common background
of unstable symptoms (within 12h for unstable angina and
non-ST-elevation MI, and within 30 days for patients
undergoing an intervention), they were nevertheless quite
heterogeneous. The assumption was made that once
ischemia is present, the mechanisms that lead to cell
death are similar independently of the immediate trigger to
ischemia, with major participation of the NHE.
Risk features were selected for each of the entry categories
in order to ensure an event rate greater than 10% in each. In
UA/NSTEMI, the severity of the presenting chest pain,
ischemic ST–T changes, post-MI angina, and elevated
serum levels of CK-MB and of troponin T or I are markers of
risk [1]. The criteria defined by the American College of Car-
diologists/American Heart Association [13] were used to
define high-risk lesions for PCI; the criteria used for high-risk
CABG are generally well accepted. Troponin T and I were
not used as markers of an end-point MI, because very few
hospitals were using the test at the time of the study.
As a consequence of patient selection and study design, the
results of the GUARDIAN trial may not apply to many other
clinical situations for which cell protection is warranted. Such
situations are evolving ischemia and MI, with or without
reperfusion, reversible ischemic left ventricular dysfunction,
ischemia and reperfusion arrhythmias, and left ventricular
remodeling. Trials with different study designs will be
required to answer these very important clinical issues.
Dose selection
In the absence of adequate surrogate end-points of effi-
cacy in the indications studied in the present trial, the
dose selection was based on preclinical data and phase 1
studies in humans. Thus, the low and high ranges of the
presumably effective doses were extrapolated from in vivo
and  in vitro experimental data that had shown dose-
related inhibition of the NHE system and a correlation
between doses, blood concentration, and infarct size
reduction [8]. In the rabbit model of 30-min ischemia,
infarct size was reduced by 50% at IC50 (57ng/ml) and by
http://cvm.controlled-trials.com/content/1/1/059
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(200ng/ml) [10]. Similar IC50 values were found in ex vivo
human platelet studies (45–72ng/ml), with concentrations
of 200ng/ml producing 80% inhibition (internal data;
Aventis); the 80 and 120mg doses in these studies inhib-
ited NHE exchange by 90–100% shortly after administra-
tion. With an 8-h (three times a day) dosing interval,
trough concentrations of 129ng/ml were achieved with
the 80-mg dose, and of 278ng/ml with the 120-mg dose.
Accordingly, trough NHE inhibition levels of 74 and 85%,
respectively, were expected with the two high doses. The
20-mg dosage arm was introduced to cover the full range
of the expected dose/response, because clinical effects of
lower dosages could not be excluded. It was expected
that this low-dose arm would be dropped during the
course of the trial at one interim analysis. Such an action
was not undertaken because it was not deemed appropri-
ate by the DSMB.
Doses higher than 120mg were not studied. This is
because phase 1 studies had suggested that the maxi-
mally tolerated dose in humans was 140mg, higher doses
administered within 30 min being associated with frequent
side effects, such as nausea, flushing, taste disturbance,
paresthesia, vertigo, and diaphoresis, occurring shortly
after drug administration (internal data, Aventis), and an
increase in blood pressure. In order to avoid high peak
drug concentrations and optimize tolerability, the drug was
administered over a period of 1h in the GUARDIAN trial.
The drug regimens used resulted in no excess significant
side effects compared with placebo and no changes in
blood pressure [20]. A report on the preliminary results of
the trial showed no effects of the two lower doses, sug-
gesting undertitration of the drug was used and, also, a
need for a near complete inhibition of the exchanger for
clinical benefit [20].
Duration of treatment
The intent of the protocol was to administer the study drug
for the duration of the period of high risk without unduly
prolonging the administration of an experimental drug and
the duration of hospitalization stay. In UA/NSTEMI, the
period of higher risk extends only for a couple of days in the
absence of recurrent ischemia, and the risk decreases after
a 24-h pain-free period. A new risk is introduced when an
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Table 3
Concomitant cardiovascular illnesses and risk factors in the overall population
Cariporide
All (n=11 587) Placebo (n=2909) 20 mg (n=2908) 80 mg (n=2887) 120 mg (n=2883)
Median age (years) 66.0 65 66 66 66
Sex (% male) 69.9 70.0 70.2 69.3 69.9
Smoking status (%)
Current 22.8 23.7 22.1 23.0 22.5
Ex smoker 44.7 44.6 45.1 44.4 44.6
MI at study entry (%) 10.4 10.0 11.1 10.4 10.1
History of (%)
Stable angina 24.1 23.8 23.9 23.6 25.0
Unstable angina 58.8 58.0 59.9 59.4 58.0
MI 44.5 44.0 45.4 44.6 43.9
Congestive heart failure 7.7 7.1 8.3 7.4 7.9
Hypertension 53.1 51.8 53.7 53.3 53.5
Cerebrovascular disease 6.1 5.4 6.0 6.2 6.7
Peripheral vascular disease 13.5 12.9 13.9 13.9 13.1
Cardiac arrhythmia 12.2 11.7 13.0 11.5 12.4
Hypercholesterolemia 55.0 54.3 55.1 55.9 54.8
NIDDM 19.7 19.2 20.2 20.5 18.9
IDDM 7.1 6.1 7.2 7.1 8.0
IDDM, insulin-dependent diabetes mellitus; NIDDM, noninsulin-dependent diabetes mellitus.
Table 2
Trial performance
Total UA/NSTEMI PCI CABG
Enrolment
Projected 9 000 40–50% 20–35% 10–20%
Actual* 11 590 45% 30% 25%
Event rate
Projected 13.12% 10–15% 10–15% 20–25%
Actual 12.95% 12.72% 10.91% 15.78%
*The total number of patients recruited was readjusted followed a
blinded interim analysis that showed an event rate slightly lower than
expected.intervention is performed. With PCI and CABG the high-
risk period extends for 12–24h after the procedure. In
order to accommodate these different situations, the dura-
tion of treatment was left open, relying on the medical judg-
ment of the investigator and the treating physician to define
the at-risk period for individual patients. It was recom-
mended to administer the drug for the duration of the stay
in the intensive or coronary care unit and for at least 2 days
(six doses). The drug could be discontinued earlier after an
uneventful percutaneous intervention.
Status of the trial
A total of 11950 patients have been recruited into the trial
from May 15 1997 to August 15 1998. This rapid pace in
recruitment was not matched by the performance in study
monitoring and end-point validation. Table 2 summarizes
the final versus expected performance with regard to
recruitment, entry diagnosis, and event rates. Table 3
describes the baseline characteristics of the populations
enroled in the four study groups.
Conclusion
The GUARDIAN trial had many challenging features. It
originally tested a novel pharmacologic agent (cariporide)
and the hypothesis that inhibition of the NHE that is
believed to play a fundamental in producing cell necrosis
during ischemia (NHE) would prevent MI. The trial was
designed as a phase 2/phase 3 trial, evaluating the
dose/response relationship for safety and efficacy. It was
also designed to identify evidence of benefit across a wide
spectrum of at-risk patients, presumably because of an
important and common role of the NHE. To achieve these
aims, the study employed convincing end-points and pre-
vention of MI rather than reduction in infarct size, a sample
size driven by the event rate, a tight validation process for
these end-points, and a nonparametric covariance adjust-
ment analysis method.
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